<DOC>
	<DOCNO>NCT01405599</DOCNO>
	<brief_summary>Evaluation effect hepatic impairment pharmacokinetics ulimorelin single intravenous ( IV ) dose order identify potential patient risk term severity hepatic dysfunction determine whether dosage adjust .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Ulimorelin Subjects With Hepatic Impairment Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Main Criteria Inclusion All Subjects : Adult male female subject age 18 75 year ( inclusive ) Able understand willing sign inform consent form ( ICF ) able comply study restriction Female subject must postmenopausal ( least 1 year confirm serum folliclestimulating hormone ( FSH ) screen ) , surgically sterile , practice true abstinence and/or must use adequate contraception duration study ( e.g . contraceptive implant , injectables , oral contraceptive , intrauterine device and/or barrier method ( condom/occlusive cap spermicidal foam/gel/film/cream/suppository ) ) Females childbearing potential must negative pregnancy test screen Day 1 Weight ≥ 50 kg ≤ 200 kg Body mass index ( BMI ) ≤ 40.0 kg/m2 , BMI ( kg/m2 ) = Body weight ( kg ) /Height2 ( m2 ) Inclusion Criteria Hepatic Impairment Subjects ( addition criterion subject ) : Documented mild , moderate severe hepatic impairment define either ChildPugh A , B C screen Stable hepatic impairment , define clinically significant change disease status within last 30 day screen , document subject 's recent medical history ( e.g. , worsen clinical sign hepatic impairment worsen total bilirubin prothrombin time 50 % ) Must stable dose medication and/or treatment regimen least 2 week dose study medication Subjects history substance abuse may enrol provide abused drug alcohol least 6 month precede study Inclusion Criteria Healthy Subjects ( addition criterion subject ) : Subjects normal hepatic function , liver parameter within normal range unless approve Sponsor 's Medical Representative Subjects use prescription drug nonprescription drug , include overthecounter medication , nonroutine vitamin herbal product within 3 week prior dose investigational product [ use oral contraceptive , diuretic , noncardioselective betablockers , topically apply medication ( eye/nosedrops cream ) occasional use metaclopramide , ibuprofen paracetamol permit ] . Use medication discuss agree inclusion subject Medical Monitor Sponsor 's medical representative Criteria Exclusion All Subjects : Known suspect allergy trial product related product History multiple and/or severe allergy drug food history severe anaphylactic reaction Participation another investigational drug trial within 30 day prior dose ( 5 time half life drug longer ) Acute illness within 14 day prior dose unless mild severity approve Investigator Sponsor 's medical representative History drug abuse positive urine drug screen ( due concomitant medication ) Screening and/or Day 1 Ingestion alcohol caffeine within 24 hour prior dose duration study Donation 450mL blood / blood product 30 day prior dose , and/or blood donation 30 day prior dose Positive result screen test HIV1 antibody , HIV2 antibodies HIV1 antigen accord locally use diagnostic test Creatinine clearance &lt; 50mL/minute , estimate use serum creatinine formula [ ( 140 age year ) × weight kg ] / [ ( 72 × serum creatinine mg/dL ) × 0.85 female subject ] Consumption Seville orange , grapefruit grapefruit juice , star fruit exotic fruit 7 day prior first dose study medication entire duration study Clinically significant abnormal haematology , biochemistry , coagulation urinalysis screening test , judge Investigator abnormal value expect consider underlie disease Subject disease condition Investigator feel would interfere trial outcome compliance except condition associate hepatic impairment group subject compromise hepatic function Uncontrolled treated/untreated hypertension ( systolic blood pressure ≥ 160 mmHg /or diastolic blood pressure ≥ 105 mmHg ) Use prescription overthecounter medication extensively bound α1acid glycoprotein ( AAG ) Investigator Sponsor feel would interfere trial outcome History cancer ( judge full remission ) presence cancer ( except basal cell skin cancer squamous cell skin cancer ) judge Investigator Subject undergone liver transplantation Not able willing refrain smoking inpatient period Any condition would make subject unsuitable clinical trial participation judge Investigator Exclusion Criteria Hepatic Impairment Subjects ( addition criterion subject ) : Any medical surgical condition , exclude underlie liver disease , may significantly interfere pharmacokinetics study drug Fluctuating rapidly deteriorate hepatic function Exclusion Criteria Healthy Subjects ( addition criterion subject ) : Subjects clinically significant illness judge Investigator Exposure three new chemical entity within 12 month prior first dose day Known acute hepatitis viral , alcoholic , toxic autoimmunological aetiology within last 6 month . Positive result screen test Hepatitis B antigen Hepatitis C antibodies accord locally use diagnostic test Strenuous exercise within 48 hour prior dose duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ulimorelin</keyword>
	<keyword>Hepatic Impairment</keyword>
</DOC>